marrow homing rates of no tri12 and tri12 CLL cells upon treatment with the anti-CD49d mAb HP2.1. Homing rates were normalized as described [8, 9] : number of human cells Control analysis to Figure 3B : (i) CD49d surface expression levels of no tri12 and tri12 CLL samples used in Figure 3B were split into groups with low (n = 6) or high (n = 5) CD49d levels according to the median CD49d expression. Tri12 CLL samples are marked in grey, no tri12 CLL cells in black.
(ii) CLL samples were grouped using the median CD49d expression as the cutoff, and total arrests to CXCL12/VCAM-1 were normalized to VCAM-1 controls.
(B) Control analysis to Figure 3B : (i) CXCR4 surface expression levels of no tri12 and tri12 CLL samples used in Figure 3B were split into groups with low (n = 5) or high (n = 6) CXCR4 levels according to the median CXCR4 expression. Tri12 CLL samples are marked in grey, as described above.
(ii) CLL samples were grouped using the median CXCR4 expression as the cutoff, and total arrests to CXCL12/VCAM-1 were normalized to VCAM-1 controls. (C) Control analysis to Figure 6B : (i) CCR7 surface expression levels of no tri12 and tri12 CLL samples used in Figure 6B were split into groups with low (n = 5) or high (n = 6)
CD49d levels according to the median CCR7 expression. Tri12 CLL samples are marked in grey, as described above.
(ii) CLL samples were grouped using the median CCR7 expression as the cutoff, and total arrests to CCL21/VCAM-1 were normalized to VCAM-1 controls.
Scatter plots, the middle line indicates the median. Columns represent the mean ± SD.
Supplemental Table 1 : Detailed patient characteristics. Rai stage was defined according to Rai et al. [1] Treatment status: CD49d expression (cutoff 30%) was analyzed as described [2, 3] in patients that were either chemonaive or not treated within the last 6 months. The mutational status of the IgVH genes was defined by the percentage of sequence homology with the germline equivalent (M, mutated, <98% homology; UM, unmutated, ≥98% homology). ZAP-70 expression was evaluated as recommended [4] (low, NKT/B ratio >3.5;
high, NKT/B ratio <3.1). CD38 status was defined as described [5] (low, <30%; high, ≥30%).
Chromosomal aberrations were determined according to Döhner et al. [6] Notch-1 mutational status was defined by amplification refractory mutation system (ARMS) PCR according to Rossi et al. [7] . ND, not determined. Table 2 : Subgroup analysis of the Notch-1 mutational status of no tri12 and tri12 CLL cells. Clinical and prognostic markers were analyzed as described in the legend to Supplemental Table 1 . Notch-1 mutational status was defined by amplification refractory mutation system (ARMS) PCR according to Rossi et al. [7] . ND, not determined.
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